News | March 24, 2026
Bayer wins world-first nod in Japan for low-dose MRI contrast agent
Call it a major breakthrough for diagnostic imaging
Call it a major breakthrough for diagnostic imaging
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits
The facility features 2,176 high-performance GPUs across the US and Europe
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
Subscribe To Our Newsletter & Stay Updated
